I suppose that TA has had some impact on NBIX as TA followers move with the Red and Green indicators. But, IMHO, Nbix is not a TA play as much as it is a fundamentals play.
With a decision point looming on Indiplon, and a deep pipeline in the works, at some point NBIX will become a known biotech commodity. If Indiplon is approved, we will likely be watching commercials for it during the NCAA basketball tournement. The exposure will open the eyes of many investors to the company, and I think this will be the catalyst for significant long term returns.
It is OK by me to apply TA to NBIX or whatever you want, but realistically, given the massive institutional position in the stock, its just hard to believe that is truly influential.
Of course it does provide some message board fodder, and thats good too, since the NBIX message board is slow like an italian ices stand in winter.
Lastly, I've been trading NBIX in and out, trying to take advantage of the current volitility, with some success.
I appreciate the post, TA. One comment though, NBI will not do any DTC advertising for the first 6 months post Indiplon launch (Sepracor did the same thing after Lunesta launched) but you are right that once appoval comes, NBI will become a much hotter topic in pharmaceutical/biotech circles.
The driving studies done in Europe that were announced at the 3Q financial report will do wonders once Indiplon launches. I think Sonata is the only GABA-a to have done driving studies and they aren't much of a player to begin with.